75000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - Nature of the Business and Basis of Presentation
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - Fair Value Measurements and Marketable Securities
link:presentationLink
link:calculationLink
link:definitionLink
995485 - Disclosure - Accrued Expenses and Other Current Liabilities
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - Equity Transactions
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Deferred Royalty Obligation
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - Common Stock
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - Share-Based Compensation
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - Government Contracts
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - License, Collaboration and Service Agreements
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - Liability Related to the Sale of Future Royalties
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Australia Research and Development Tax Incentive
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Restructuring
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - Income Taxes
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Segment Information
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - Net Loss per Share
link:presentationLink
link:calculationLink
link:definitionLink
995625 - Disclosure - Subsequent Events
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Summary of Significant Accounting Policies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995655 - Disclosure - Fair Value Measurements and Marketable Securities (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - Share-Based Compensation (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - License, Collaboration and Service Agreements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Liability Related to the Sale of Future Royalties (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Restructuring (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - Segment Information (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995725 - Disclosure - Net Loss per Share (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - Subsequent Events (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Fair Value Measurements and Marketable Securities - Summary of Financial Assets and Liabilities Measured at Fair Value Recurring Basis (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Fair Value Measurements and Marketable Securities - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - Common Stock - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Share-Based Compensation - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - Share-Based Compensation - Summary of the stock option activity (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Stock-Based Compensation - Summary of fair value of stock option awards granted to employees (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Share-Based Compensation - Restricted Stock Units (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995875 - Disclosure - Commitments and Contingencies (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995885 - Disclosure - Government Contract - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - License, Collaboration and Service Agreements - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995905 - Disclosure - License, Collaboration and Service Agreements - Schedule of remaining potential milestone payments (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995915 - Disclosure - License, Collaboration and Service Agreements - Schedule of Remaining Potential Milestone Payments (Parenthetical) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995925 - Disclosure - Restructuring - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995935 - Disclosure - Restructuring - Schedule of restructuring related charges (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995945 - Disclosure - Restructuring -Schedule of Restructuring charges included in Accrued expenses and other current liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995955 - Disclosure - Income Taxes (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995965 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995975 - Disclosure - Net Loss per Share - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995985 - Disclosure - Net Loss per Share - Summary of Shares Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995995 - Disclosure - Segment Information - Schedule of Reportable Segment Net Revenues and Loss (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996005 - Disclosure - Segment Information (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996015 - Disclosure - Subsequent Events (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
Gsk Spa [Member]
GSK SPA [Member]
GSK SPA [Member]
Net Sales Greater Than Four Hundred Million [Member]
Net Sales Greater Than Four Hundred Million [Member]
Net annual sales greater than $400.0 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Forfeited or cancelled
Nature of business and basis of presentation.
Nature Of Business And Basis Of Presentation [Abstract]
Balance at end of period
Balance at beginning of period
Restructuring Reserve
Restructuring Reserve, Total
Contractors [Abstract]
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Preferred Stock, Shares Issued, Total
Preferred Stock, Shares Issued
Preferred stock, shares/units issued
Statement of Financial Position Location, Balance [Domain]
Balance Sheet Location
Increase (Decrease) in Accounts Payable, Total
Increase (Decrease) in Accounts Payable
Accounts payable
Defense Threat Reduction Agency.
Defense Threat Reduction Agency [Member]
DTRA [Member]
Plan Name [Axis]
Research and Development Expense [Abstract]
Less:
Equity [Abstract]
Entity Current Reporting Status
Entity Current Reporting Status
The entire disclosure for research and development tax incentive.
Research And Development Tax Incentive [Text Block]
Australia Research and Development Tax Incentive
Operating Expenses [Abstract]
Operating expenses:
SPA Agreement with FDA [Member]
SPA Agreement with FDA [Member]
Fair Value, Inputs, Level 2 [Member]
Level 2 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price
Commitments and Contingencies Disclosure [Text Block]
Commitments and Contingencies
Common stock authorized for issuance
Common Stock, Shares Authorized
Common stock, shares authorized
Option Indexed to Issuer's Equity, Type [Axis]
Option Indexed to Issuer's Equity, Type
Product and Service [Axis]
Product and Service
Document Fiscal Period Focus
Document Fiscal Period Focus
Government Grants Revenue
Government Grants Revenue
Cumulative Revenue
Entity Shell Company
Entity Shell Company
Other Accrued Liabilities, Current
Accrued other
Mr Shukla [Member]
Mr Shukla Member
Mr Shukla Member
Segment Reporting, Policy [Policy Text Block]
Segment Information
Cash and Cash Equivalent
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value, Ending Balance
Cash and Cash Equivalents, at Carrying Value, Beginning Balance
Cash and Cash Equivalents, at Carrying Value, Total
At-the-market offering program.
At The Market Offering Program [Member]
At-The-Market Offering Program [Member]
Research and Development Arrangement, Contract to Perform for Others, Type [Axis]
Research and Development Arrangement, Contract to Perform for Others, Type
Stock Issued During Period, Shares, Conversion of Units
Issuance of common stock upon the vesting of restricted stock units and performance stock units, shares
Common Stock, Shares, Issued, Total
Common Stock, Shares, Issued
Common stock, shares/units issued
Increase in shares of common stock for issuance
Asset Class [Domain]
Asset Class
Aggregate Retention Awards Cash Bonus
Aggregate Retention Awards Cash Bonus
Statement [Table]
Statement [Table]
Covering period of non-diluitve funding.
Covering Period Of Non Diluitve Funding
Non-dilutive funding period
Share-Based Payment Arrangement, Disclosure [Abstract]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted average grant-date fair value of awards granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent
Exercise price per share of stock options as a percentage of fair market value of share of common stock
Research And Development Services Related To Upcoming Milestones [Member]
Research And Development Services Related To Upcoming Milestones [Member]
Statement [Line Items]
Statement [Line Items]
Revenue Recognition - Collaboration Revenue
Revenue from Contract with Customer [Policy Text Block]
Entity Filer Category
Entity Filer Category
Total liabilities and stockholders' equity
Liabilities and Equity
Payables and Accruals [Abstract]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Exercisable at March 31, 2026
Restructuring Type [Axis]
Long-Lived Tangible Asset [Axis]
Long-Lived Tangible Asset
Severance and other employee costs
Severance Costs
Earnings per share.
Earnings Per Share [Table]
Earnings Per Share [Table]
Potential Amount of Committed Funding
Potential Amount of Committed Funding
Potential Amount of Committed Funding
Prepaid Expenses and Other Current Assets [Member]
Prepaid Asset [Member]
Laboratory equipment.
Laboratory Equipment [Member]
Laboratory Equipment [Member]
Restructuring and Related Costs [Table Text Block]
Schedule of restructuring related charges
Cash and Cash Equivalents, Fair Value Disclosure
Total cash equivalents
Total cash
Shares Issued, Price Per Share
Share price
Milestone payment upon submission of a new drug application.
Milestone Payment Upon Submission of a New Drug Application
Milestone payment
Subsequent Event [Line Items]
Restructuring charges table text block
Restructuring charges table text block
Schedule of restructuring charges
Accrued expenses and other current liabilities.
Accrued Expenses And Other Current Liabilities
Accrued expenses and other current liabilities
Total accrued expenses and other current liabilities
Estimated useful lives of assets.
Estimated Useful Lives Of Assets Table [Text Block]
Estimated Useful Lives of Assets
Investment Income, Interest
Interest income
Interest income
Geographical [Domain]
Schedule of Performance Obligation Along with Standalone Selling Price and Transaction Price Allocated
Schedule Of Performance Obligation Along With Standalone Selling Price And Transaction Price Allocated Table Text Block
Schedule of performance obligation along with standalone selling price and transaction price allocated.
Contact extension term.
Contact Extension Term
Contact extension term
Schedule of Reportable Segment Net Revenues and Loss
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]
Potential amount additional funding awarded.
Potential Amount Additional Funding Awarded
Potential amount additional funding awarded
Additional Paid in Capital, Common Stock, Ending Balance
Additional Paid in Capital, Common Stock, Beginning Balance
Additional Paid in Capital, Common Stock
Additional paid-in capital
Remaining transaction price allocated to the performance obligations
Remaining Transaction price allocated to performance obligations.
Remaining Transaction Price Allocated To Performance Obligations
Significant Accounting Policies [Text Block]
Summary of Significant Accounting Policies
Property, Plant and Equipment [Line Items]
Property Plant And Equipment [Line Items]
Workforce reduction, percent
Workforce Reduction, Percent
Workforce Reduction, Percent
Share based compensation award performance based vesting criteria.
Share Based Compensation Award Performance Based Vesting Criteria [Member]
Performance-based Vesting Criteria [Member]
Share-based compensation arrangement by share-based payment award, maximum number of shares to be incremented.
Sharebased Compensation Arrangement By Sharebased Payment Award Maximum Number Of Shares To Be Incremented
Number of shares to be incremented
Vesting [Domain]
Vesting
Authorized offering value
Liabilities and stockholders equity authorized offering value.
Liabilities And Stockholders Equity Authorized Offering Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Share based compensation options granted
Granted
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders
Milestones payment received
Milestones payment received
Milestones payment received
Increase (Decrease) in Other Receivables
Other receivables
Earnings Per Share, Basic
Earnings Per Share, Basic, Total
Net loss per share attributable to common stockholders, basic
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Outstanding as of December 31, 2025
Outstanding as of March 31, 2026
Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]
Summary of Gross Unrealized Gains and Losses of Marketable Securities
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
Weighted average grant-date fair value of awards vested and released
Savior service agreement.
Savior Service Agreement [Member]
Savior Service Agreement [Member]
Contract term.
Contract Term
Contract term
Liabilities, Current
Total current liabilities
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Number Of Employees Before Restructuring Initiative
Number Of Employees Before Restructuring Initiative
Award received for research and development.
Award Received For Research And Development
Award received for clinical development
Entity Small Business
Entity Small Business
Grant Revenue [Member]
Grant Revenue [Member]
Grant Revenue
Potential Amount Subsequently Funding Awarded
Potential Amount Subsequently Funding Awarded
Potential Amount Subsequently Funding Awarded
Research and Development [Abstract]
Retained Earnings (Accumulated Deficit), Beginning Balance
Retained Earnings (Accumulated Deficit), Ending Balance
Retained Earnings (Accumulated Deficit), Total
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Accumulated deficit
General And Administrative Personnel Related Including Share Based Compensation [Member]
General And Administrative Personnel Related Including Share Based Compensation Member
General and administrative personnel related (including share-based compensation)
Preferred Stock [Member]
Forfeited or cancelled
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Forfeited or cancelled
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value
Aggregate intrinsic value of stock options exercised
Tebipenem HBr [Member]
Tebipenem HBr [Member]
Tebipenem HBr
Share-Based Payment Arrangement [Text Block]
Share-Based Compensation
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Glaxo Smith Kline [Member]
Glaxo Smith Kline [Member]
GSK [Member]
Amendment Flag
Amendment Flag
Product and Service [Domain]
Product and Service
Non-cash lease cost.
Non Cash Lease Cost
Non-cash lease cost
GSK License Agreement [Member]
GSK License Agreement [Member]
GSK License Agreement [Member]
Amendment 2 [Member]
Amendment Two [Member]
Amendment Two Member
Earnings Per Share, Policy [Policy Text Block]
Net Income (Loss) per Share
Liabilities and Equity [Abstract]
Liabilities and Stockholders' Equity
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Net cash (used in) provided by operating activities
Increase (Decrease) in Operating Lease Liability
Operating lease liability
Loss on extinguishment of liability related to the sale of future royalties
Loss on extinguishment of liability related to the sale of future royalties
Loss on extinguishment of liability related to the sale of future royalties
Loss on extinguishment of liability related to the sale of future royalties
Deferred Revenue Non Current Related Partys
Deferred Revenue Non Current Related Partys
Deferred revenue, non-current - related party
Common Stock [Member]
Common Stock [Member]
Research and development services performance obligation
Milestone Allocated Research And Development Services
Milestone Allocated Research And Development Services
Fair Value Disclosure, off-Balance-Sheet Risks, Amount, Asset
Off-balance sheet risk
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Granted
2019 Inducement Plan [Member]
Two Thousand And Nineteen Inducement Equity Incentive Plan [Member]
Two thousand and nineteen Inducement equity incentive plan.
Research and Development Arrangement, Contract to Perform for Others, Type [Domain]
Research and Development Arrangement, Contract to Perform for Others, Type
Change in subsequent payments
Change in subsequent payments
Reduction In Subsequent Payments by GSK to the Company
Entity Address, Address Line One
Entity Address, Address Line One
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Summary of assumptions used to Determine fair value of stock option awards granted to employees
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV
Earnings Per Share [Abstract]
Income Tax, Policy [Policy Text Block]
Income Taxes
Statement of Financial Position Location, Balance [Axis]
Balance Sheet Location
Series A B C and D convertible preferred stock.
Series A B C And D Convertible Preferred Stock [Member]
Series A, B, C and D Convertible Preferred Stock [Member]
Operating Lease, Right-of-Use Asset
Operating lease right of use assets
Unrealized loss on available-for-sale securities
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
Net unrealized gains (losses) on securities
Document Type
Document Type
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative
Entity Central Index Key
Entity Central Index Key
Research And Development Personnel Related Including Share Based Compensation [Member]
Research And Development Personnel Related Including Share Based Compensation Member
Research and development personnel related (including share-based compensation)
Net decrease in cash and cash equivalents:
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Subsequent Event Type [Domain]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]
Summary of Activity of Options and RSUs of Performance-Based Options
Potential amount initial funding awarded.
Potential Amount Initial Funding Awarded
Potential amount initial funding awarded
Fair Value, Liabilities of Level 2 to Level 1 Transfers Amount
Fair Value, Liabilities of Level 2 to Level 1 Transfers Amount
Common Stock, Par or Stated Value Per Share
Common stock, par value
Cantor Fitzgerald & Co.
Cantor Fitzgerald Co [Member]
Cantor Fitzgerald & Co [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Outstanding as of September 30, 2022
Outstanding as of December 31, 2025
Series C convertible preferred stock.
Series C Convertible Preferred Stock [Member]
Series C Convertible Preferred Stock [Member]
Net Sales Greater Than Two Hundred Million [Member]
Net Sales Greater Than Two Hundred Million [Member]
Net annual sales greater than $200.0 [Member]
Collaboration receivable related parties non current
Collaboration Receivable Related Parties Non Current
Collaboration receivable, non-current - related party
Net Sales Greater Than One Thousand Million [Member]
Net Sales Greater Than One Thousand Million [Member]
Net annual sales greater than $1,000.0 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Issuance of common stock upon the exercise of stock options, shares
Exercised
Development milestone [Member]
Development milestone [Member]
Restructuring and Reduction in Workforce [Member]
Restructuring and Reduction in Workforce [Member]
Restructuring and Reduction in Workforce [Member]
Current Fiscal Year End Date
Current Fiscal Year End Date
Net Sales Greater Than Five Hundred Million [Member]
Net Sales Greater Than Five Hundred Million [Member]
Net annual sales greater than $500.0 [Member]
Document Quarterly Report
Document Quarterly Report
Performance-Based Awards [Member]
Performance-Based Awards [Member]
Entity Address, State or Province
Entity Address, State or Province
Stock Issued During Period, Value, Conversion of Convertible Securities
Conversion of convertible preferred stock to common stock
Issuance of Common Stock, conversion of Preferred Stock to Common Stock
Contract termination period.
Contract Termination Period
Contract termination period
License agreement research and development expense related to achievement of regulatory milestones.
License Agreement Research And Development Expense Related To Achievement Of Regulatory Milestones
License agreement research and development expense related to achievement of regulatory milestones
Preferred Stock, Shares Outstanding, Ending Balance
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred Stock, Shares Outstanding
Preferred stock, shares/units outstanding
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Total comprehensive loss
Increase Decrease In Collaboration Receivable Related Party Current And NonCurrent
Increase Decrease In Collaboration Receivable Related Party Current And NonCurrent
Collaboration receivable, current and non-current - related party
Collaboration receivable, current and non-current - related party
2017 Plan [Member]
Two Thousand Seventeen Stock Incentive Plan [Member]
Two thousand seventeen stock incentive plan.
Research and Development Expense, Policy [Policy Text Block]
Research and Development Costs
Common stock reserved for issuance
Common Stock, Capital Shares Reserved for Future Issuance
Biomedical Advanced Research and Development Authority.
Biomedical Advanced Research And Development Authority [Member]
BARDA [Member]
Concentration Risk, Credit Risk, Financial Instruments, off-Balance-Sheet Risk
Off-balance sheet risk description
Geographical [Axis]
Gross proceeds from issuance of common and preferred stock
Proceeds From Issuance Follow On Public Offering Gross
Proceeds from issuance follow on public offering gross.
Earnings per share.
Earnings Per Share [Line Items]
Earnings Per Share [Line Items]
Milestone Achievement Research And Development Services
Milestone Achievement Research And Development Services
Milestone Achievement Research And Development Services
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Summary of Share-Based Compensation Expense
Second option.
Second Option [Member]
Second Option [member]
Stock Issued During Period, Value, Stock Options Exercised
Issuance of common stock upon the exercise of stock options
Comprehensive Income, Policy [Policy Text Block]
Comprehensive Income (Loss)
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]
Accrued Expenses and Other Current Liabilities
Collaborative Arrangement Disclosure [Text Block]
License, Collaboration and Service Agreements
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Other comprehensive gain (loss):
Unvested Performance Stock Units [Member]
Performance Shares [Member]
License agreement milestone payment upon completion and delivery of results of a clinical study.
License Agreement Milestone Payment Upon Completion And Delivery Of Results Of Clinical Study
Potential milestone payments upon completion and delivery of results of a clinical study
Subsequent Event [Member]
Subsequent Events
Marketable Securities, Policy [Policy Text Block]
Marketable Securities
Deferred revenue, current
Deferred Revenue, Current, Total
Deferred Revenue, Current
DoD, Congressionally Directed Medical Research Programs and Joint Warfighter Medical Research Program.
Department Of Defense Congressionally Directed Medical Research Programs And Joint Warfighter Medical Research Program [Member]
DoD, CDMRP and JWMRP [Member]
Other Assets, Noncurrent, Total
Other Assets, Noncurrent
Other assets
Antidilutive Securities [Axis]
Antidilutive Securities
Revenue, Product and Service [Extensible Enumeration]
Type of Revenue [Extensible List]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Outstanding as of March 31, 2026 - vested and expected to vest
Potential grant amount exercised.
Potential Grant Amount Exercised
Potential grant amount exercised
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Tebipenem HBr Program [Member]
tebipenem HBr program
Tebipenem HBr Program [Member]
Derivative Liability, Total
Derivative Liability
Liability Related to the Sale of Future Royalties
Share-based compensation arrangement by share-based payment award, options, vested and expected to vest, equal monthly installments.
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Equal Monthly Installments
Equal monthly installments
Performance Obligation Allocated Transaction Price
Performance Obligation Allocated Transaction Price
Performance Obligation Allocated Transaction Price
Preferred Stock, Value, Issued, Ending Balance
Preferred Stock, Value, Issued, Beginning Balance
Preferred Stock, Value, Issued, Total
Preferred Stock, Value, Issued
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and December 31, 2025
Minimum [Member]
Minimum [Member]
Assets, Current [Abstract]
Current assets:
Government tax incentives policy
Government Tax Incentives Policy Policy [Text Block]
Government Tax Incentives
Upfront Payment Received
Upfront payment received
Upfront payment received.
Level 3 [Member]
Fair Value, Inputs, Level 3 [Member]
First option.
First Option [Member]
First Option [Member]
Segment Reporting [Abstract]
Pfizer Inc [Member]
Pfizer Inc Member
Pfizer Inc Member.
Summary of Financial Assets and Liabilities Measured at Fair Value Recurring Basis
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Liabilities, Current [Abstract]
Current liabilities:
Restructuring
Restructuring and Related Activities Disclosure [Text Block]
Shares, Outstanding
Balances, Shares
Balances, Shares
Sublease income
Sublease Income
Meiji license agreement.
Meiji License Agreement [Member]
Meiji License Agreement [Member]
Commitments and Contingencies
Commitments and contingencies (Note 7)
Lessee, Leases [Policy Text Block]
Leases
Liability for Future Policy Benefit [Policy Text Block]
Liability Related to the Sale of Future Royalties
General and Administrative Expense [Member]
General and Administrative Expenses [Member]
Forecast [Member]
Royalty Guarantees, Commitments, Amount
Commitments Amount
License agreement payment of research and development expense related to achievement of regulatory milestones.
License Agreement Payment Of Research And Development Expense Related To Achievement Of Regulatory Milestones
License agreement payment of research and development expense related to achievement of regulatory milestones
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net loss
Net loss and comprehensive loss
Net loss
Accrued restructuring expenses
Accrued restructuring expenses
Accrued restructuring expenses
Weighted Average Number of Shares Outstanding, Basic
Weighted Average Number of Shares Outstanding, Basic, Total
Weighted average common shares outstanding, basic
NDA Submission [Member]
NDA Submission [Member]
Scenario [Axis]
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Long-Lived Tangible Asset [Domain]
Long-Lived Tangible Asset
Contact extension term
Contact Extension Term Month And Year
Contact extension term (month and year).
Grant revenue.
Grant Revenue
Grant revenue
Pfizer License and Share Purchase Agreements [Member]
Pfizer license and share purchase agreements member
Net Sales Greater Than Three Hundred Million [Member]
Net Sales Greater Than Three Hundred Million [Member]
Net annual sales greater than $300.0 [Member]
Subsequent Events [Text Block]
Subsequent Events
Cash
APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Share-based compensation expense
Equity, Attributable to Parent
Balances
Balances
Total stockholders' equity
Preferred Stock, Par or Stated Value Per Share
Preferred stock, par value
Patent Costs
Patent costs policy.
Patent Costs Policy Policy [Text Block]
Description of letter from Listing Qualifications Department
Description of letter from Listing Qualifications Department
Description of letter from Listing Qualifications Department
Statement of Stockholders' Equity [Abstract]
Series C Preferred Stock [Member]
Series C Preferred Stock [Member]
Antidilutive Securities Excluded From Computation Earnings Per Share [Abstract]
Antidilutive Securities Excluded From Computation Earnings Per Share [Abstract]
Sale of common stock to related party
Sale of Common Stock to Related Party
Sale of common stock to related party
Type of Restructuring [Domain]
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
Investments, Fair Value Disclosure [Abstract]
Marketable securities:
Increase (Decrease) in Deferred Revenue, Related Party
Increase (Decrease) in Deferred Revenue, Related Party
Deferred revenue - related party, current and non-current
Share-based compensation arrangement by share-based payment award, right to receive share number.
Share-based Compensation Arrangement by Share-based Payment Award, Right to Receive Share, Number
Right to receive, number of share
License and Know-How Transfer [Member]
License and know-how transfer member
Royalty Percentage
Royalty Percentage
RoyaltyPercentage
Leasehold Improvements [Member]
Leasehold Improvements [Member]
Entity Address, Address Line Two
Entity Address, Address Line Two
Fair Value Disclosures [Text Block]
Fair Value Measurements and Marketable Securities
Dr Mahadevia [Member]
Dr Mahadevia Member
Dr Mahadevia Member
UNITED STATES
UNITED STATES [Member]
Amendment Four [Member]
Amendment Four [Member]
Amendment 4 [Member]
Collaboration Receivable Related Parties Current.
Collaboration Receivable Related Parties Current
Collaboration receivable, current - related party
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Number of Shares
Segment Reporting, Other Segment Item, Amount
Other segment items
Plan Name [Domain]
Increase (Decrease) in Other Operating Assets, Total
Increase (Decrease) in Other Operating Assets
Other assets
SPR 741.
S P R Seven Four One [Member]
SPR 741 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Service agreement additional payment related to facility build out costs.
Service Agreement Additional Payment Related To Facility Build Out Costs
Service agreement additional payment related to facility build out costs
Business Description and Basis of Presentation [Text Block]
Nature of the Business and Basis of Presentation
Other Noncurrent Assets [Member]
Long-term Asset [Member]
Related Party
Related and Nonrelated Parties [Axis]
Increase (Decrease) in Income Taxes Payable
Income taxes
Gates MRI [Member]
Gates MRI.
Gates M R I [Member]
Property, Plant and Equipment, Policy [Policy Text Block]
Property and Equipment
Entity Address, City or Town
Entity Address, City or Town
Security Exchange Name
Security Exchange Name
Europe [Member]
Europe [Member]
Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Total
Debt Securities, Available-for-Sale, Unrealized Gain (Loss)
Debt securities, available-for-sale, unrealized gains (losses)
Non-refundable supervision fee related to commercial manufacturing facility.
Non Refundable Supervision Fee Related To Commercial Manufacturing Facility
Non-refundable supervision fee related to commercial manufacturing facility
Fourth Milestone [Member]
Fourth Milestone [Member]
Fourth Milestone [Member]
Increase in overall potential award.
Increase In Overall Potential Award
Overall potential award increased
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value
Weighted average grant-date fair value of awards forfeited or cancelled
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name
Second Anniversary of First Commercial Sale [Member]
Second Anniversary of First Commercial Sale [Member]
Second Anniversary of First Commercial Sale [Member]
Net loss before income taxes
Income (Loss) from Continuing Operations before Interest Expense, Interest Income, Income Taxes, Noncontrolling Interests, Net
Net loss before income taxes
Accretion of Series C preferred stock
Deemed dividends related to immediate accretion of beneficial conversion feature of stock.
Deemed Dividends Related To Immediate Accretion Of Beneficial Conversion Feature Of Stock
Statistical Measurement [Domain]
Statistical Measurement
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net, Total
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net
Transfer of financial liabilities into level 3 of fair value
Assets, Current
Total current assets
Share-Based Payment Arrangement, Expense
Compensation expense recognized
Document Period End Date
Document Period End Date
Fair Value Hierarchy and NAV [Domain]
Fair Value Hierarchy and NAV
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Exercisable at March 31, 2026
Total Received Milestone
Total Received Milestone
Total Received Milestone
Percentage of tax benefit recognized
Percentage of tax benefit recognized
Percentage Of Tax Benefit Recognized
Statement of Financial Position [Abstract]
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units (RSUs) [Member]
Unvested Restricted Stock Units [Member]
Government contracts.
Government Contracts [Line Items]
Government Contracts [Line Items]
Clinical trial and other research contract costs and accruals policy.
Clinical Trial And Other Research Contract Costs And Accruals Policy Policy [Text Block]
External Research and Development Costs and Accruals
SPR206
SPR206 [Member]
SPR206 [Member]
Number of equity compensation plans.
Number Of Equity Compensation Plans
Number of equity compensation plans
Antidilutive Security, Excluded EPS Calculation [Table]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Vesting [Axis]
Vesting
Class of Stock [Axis]
Class of Stock
Other Receivables
Other receivables
Total liabilities
Liabilities
Biomedical Advanced Research And Development Authority And The Defense Threat Reduction Agency.
Biomedical Advanced Research And Development Authority And Defense Threat Reduction Agency [Member]
BARDA and DTRA [Member]
License agreement milestone payments upon achievement of clinical and regulatory milestones.
License Agreement Milestone Payments Upon Achievement Of Clinical And Regulatory Milestones
Potential milestone payment upon achievement of specified clinical and regulatory milestones
Series D Convertible Preferred Stock.
Series D Convertible Preferred Stock [Member]
Series D Convertible Preferred Stock [Member]
Write-offs
Write-offs
Restructuring Reserve, Settled without Cash
Increase (Decrease) in Deferred Revenue
Deferred revenue, current and non-current
Executive Retention Awards [Member]
Executive Retention Awards Member
Executive Retention Awards Member
Weighted Average Number of Shares Outstanding, Diluted
Weighted Average Number of Shares Outstanding, Diluted, Total
Weighted average common shares outstanding, diluted
Entity File Number
Securities Act File Number
Retention Program [Member]
Retention Program [Member]
Retention Program [Member]
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax
Unrealized gain (loss) on marketable securities
Collaboration Revenue Related Party [Member]
Collaboration Revenue Related Party [Member]
Collaboration revenue - related party
Potential Commercial Milestone Payments
Commercial Milestone Payments [Member]
Commercial Milestone Payments [Member]
Cover [Abstract]
Underwritten public offering.
Underwritten Public Offering [Member]
Underwritten Public Offering [Member]
Outstanding Accrued Expense
Outstanding Accrued Expense
Prepaid Expense and Other Assets, Current
Prepaid expenses and other current assets
Taxes Payable, Current, Total
Income taxes payable
Taxes Payable, Current
Retention Program Payable Amount
Retention Program Payable Amount
Total Retention Payments
Derivative, Gain (Loss) on Derivative, Net, Total
Derivative, Gain (Loss) on Derivative, Net
Change in fair value of derivative liability
Other Long-Term Debt, Noncurrent
Other long-term liabilities
Scenario [Domain]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized
Number of shares authorized for issuance
Number of Operating Segments
Number of operating segments
Sale of Stock [Domain]
Sale of Stock
Segment Reporting Disclosure [Text Block]
Segment Information
General and Administrative Expense, Total
General and Administrative Expense
General and administrative
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares
Vested and released
Vested and released
Vested and released
Summarizes Inducement PSU activity under all equity plans
Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
Forfeited or cancelled
Subsequent Event [Table]
Common stock withheld for taxes, Shares
Common stock withheld for taxes
Common stock withheld for taxes
Remaining Milestone Payment
Remaining milestone payment
Remaining Milestone Payment
Premium on issued of common stock
Common Stock Issued Premium Value.
Common Stock Issued Premium Value
Everest license agreement.
Everest License Agreement [Member]
Everest License Agreement [Member]
Contract termination period if no material development or commercialization occurs
Contract termination period if no material development or commercialization occurs.
Contract Termination Period If No Material Development Or Commercialization Occurs
Base period contracts.
Base Period Contracts [Member]
Base Period Contracts [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price
Weighted Average Grant Date Fair Value of Outstanding as of March 31, 2026
Weighted Average Grant Date Fair Value of Outstanding as of December 31, 2025
Cash Bonus
Cash Bonus
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Outstanding as of March 31, 2026 - vested and expected to vest
Charge to expense
Restructuring Charges
Total restructuring charges
Restructuring
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]
Weighted Average Contractual Term
Property, Plant and Equipment, Useful Life
Estimated useful life
New Accounting Pronouncements, Policy [Policy Text Block]
Recently Issued and Adopted Accounting Pronouncements
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Conversion of convertible preferred stock to common stock, shares
Stock Issued During Period, Shares, Conversion of Convertible Securities
Conversion of convertible preferred stock to common stock, shares
Deferred revenue current related party
Deferred Revenue Current Related Party
Deferred revenue, current - related party
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period
Options vesting period
Pfizer Purchase Agreement [Member]
Pfizer purchase agreement member.
Pfizer Purchase Agreement [Member]
Employee Severance [Member]
Severance and other employee costs
Lease Impairment [Member]
Lease Impairment [Member]
Lease impairment
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Risk-free interest rate, Minimum
Number Of Employees After Restructuring Initiative
Number Of Employees After Restructuring Initiative
Common stock, shares/units outstanding
Common Stock, Shares, Outstanding, Ending Balance
Common Stock, Shares, Outstanding, Beginning Balance
Common Stock, Shares, Outstanding
Operating Lease, Liability, Current
Operating lease liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Depreciation, Depletion and Amortization, Total
Depreciation, Depletion and Amortization
Depreciation and amortization
Retention Award Payable
Retention Award Payable
Retention Award Payable
Document Transition Report
Document Transition Report
Third Option [Member]
Third Option [Member]
Third Option [Member]
Operating Expenses
Total operating expenses
Number of option period for funding from government contract.
Number Of Option Period For Funding From Government Contract
Number of option period for funding from government contract
Research and Development Expense, Total
Research and Development Expense
Research and development
Impairment of long-term asset
Impairment of long-term asset
Asset Impairment Charges, Total
Asset Impairment Charges
Impairment of assets
Restructuring
Restructuring [Policy Text block]
Restructuring policies for the company.
License agreement milestone payments upon achievement of specified commercial milestone.
License Agreement Milestone Payments Upon Achievement Of Specified Commercial Milestone
Potential milestone payment upon achievement of specified commercial milestone
Total potential additional milestones
Total potential additional milestones
Revenue Recognition and Deferred Revenue [Abstract]
License agreement fixed assets related payments.
License Agreement Fixed Assets Related Payments
License agreement fixed assets related payments
Statement of Cash Flows [Abstract]
Amount Receved For Additional Clinical Study
Amount Receved For Additional Clinical Study
Amount Receved For Additional Clinical Study
Issuance of stock, value
Stock Issued During Period, Value, New Issues
Issuance of common stock, net of issuance costs
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Summary of Stock Option Activity
Equity [Text Block]
Common Stock
Net Loss per Share
Earnings Per Share [Text Block]
Revenue Recognition [Abstract]
Computer Equipment [Member]
Computer Software and Equipment [Member]
Net loss
Consolidated loss
Consolidated loss
Schedule of accrued expenses and other current liabilities table.
Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]
Schedule of Accrued Expenses and Other Current Liabilities
Vested in 2024
Vested in Future [Member]
Vested in Future [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Outstanding as of March 31, 2026
Outstanding as of December 31, 2025
Premium associated freestanding equity
Separate Account, Liability, Premium
Expected dividend yield
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Series B convertible preferred stock.
Series B Convertible Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
S P R Seven Two Zero [Member]
S P R Seven Two Zero [Member]
SPR720 [Member]
Net Sales Greater Than Seven Hundred Fifty Million [Member]
Net Sales Greater Than Seven Hundred Fifty Million [Member]
Net annual sales greater than $750.0 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Exercisable at March 31, 2026
Assets [Abstract]
Assets
Facility Related and Other [Member]
Facility Related and Other [Member]
Facility related and other
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Risk-free interest rate
Increase (Decrease) in Prepaid Expense and Other Assets, Total
Increase (Decrease) in Prepaid Expense and Other Assets
Prepaid expenses and other current assets
Restructuring and Related Activities [Abstract]
Document Fiscal Year Focus
Document Fiscal Year Focus
Additional milestone payments receivable upon achievement of certain developmental regulatory and sales milestone.
Additional Milestone Payments Receivable Upon Achievement Of Certain Developmental Regulatory And Sales Milestone
Receivable amount upon achievement of certain milestone
Accounts Payable, Current, Total
Accounts Payable, Current
Accounts payable
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net
fair value of the derivative liability
Fair value of the derivative liability
Research and Development Expense [Member]
Research and development [Member]
Percent of aggregate payment received
Percent of aggregate payment received
Restructuring Cost and Reserve [Line Items]
unrecognized compensation expense
unrecognized compensation expense
Unrecognized compensation expense
Fair Value Measurement, Policy [Policy Text Block]
Fair Value Measurements
Total Milestone
Total milestone
Total milestone
Potential grant amount awarded
Potential grant amount awarded.
Potential Grant Amount Awarded
SPR Two Thousand Six Member
SPR Two Thousand Six [Member]
SPR206 [Member]
Schedule of Changes in the Liability Related to the Sale of Future Royalties [Table Text Block]
Schedule of Changes in the Liability Related to the Sale of Future Royalties [Table Text Block]
Schedule of Changes in the Liability Related to the Sale of Future Royalties
Fair Value Disclosures [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Receivable amount upon achievement of certain milestone
Receivable Amount Upon Achievement Of Certain Milestone
Receivable amount upon achievement of certain milestone.
Net Income (Loss) Available to Common Stockholders, Basic
Net loss attributable to common stockholders
Rights [Member]
Rights Offering [Member]
Remaining Sublicence Fee Paid to Counter Party
Remaining Sublicence Fee Paid to Counter Party
Third Milestone [Member]
Third Milestone [Member]
Third Milestone [Member]
Vertex license agreement.
Vertex License Agreement [Member]
Vertex License Agreement [Member]
Share-Based Payment Arrangement [Abstract]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total
Total unrecognized compensation cost related to unvested share-based awards
Grants from government contracts disclosure.
Grants From Government Contracts Disclosure [Text Block]
Government Contract
Impairment Expense
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses
Assets, Fair Value Disclosure
Total cash equivalents and marketable securities
Sale of Stock [Axis]
Sale of Stock
Derivatives, Policy [Policy Text Block]
Derivative Liability
Initial Payments to Perform the Obligations
Initial Payments to Perform the Obligations.
Initial Payments to Perform the Obligations
Revenues
Grant revenue
Total revenues
Total revenues
Title of 12(b) Security
Title of 12(b) Security
Schedule of Segment Reporting Information, by Segment [Table]
Stock Issued During Period, Value, Conversion of Units
Issuance of common stock upon the vesting of restricted stock units and performance stock units
Accrued external research and development expenses current.
Accrued External Research And Development Expenses Current
Accrued external research and development expenses
Money Market Funds [Member]
Money Market Funds [Member]
Related and Nonrelated Parties [Domain]
Related Party
Cantab Related Agreements [Member]
Cantab Related Agreements [Member]
Cantab Related Agreements [Member]
Income Taxes
Income Tax Disclosure [Text Block]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Accrued Liabilities, Fair Value Disclosure
Derivative liability
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]
Changes in operating assets and liabilities:
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Outstanding as of December 31, 2025
Outstanding as of March 31, 2026
Income Tax Disclosure [Abstract]
Fair Value, Recurring and Nonrecurring [Table]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Other assets.
Other Assets Policy [Text Block]
Other Assets
First Milestone [Member]
First Milestone [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Accrued expenses and other current liabilities
Measurement Frequency [Domain]
Measurement Frequency
Collaboration Revenue [Member]
Collaboration Revenue [Member]
Collaboration revenue
Reduction In Workforce
Reduction In Workforce
Reduction in workforce
Statement of Income Location, Balance [Axis]
Income Statement Location
Equity offering.
Equity Offering [Text Block]
Equity Transactions
Trading Symbol
Trading Symbol
Sublicence Fee Paid to Counter Party
Sublicence Fee Paid to Counter Party
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Risk-free interest rate, Maximum
Human Capital Management Committee [Member]
Human Capital Management Committee [Member]
Subsequent Event Type [Axis]
Bonus percent
Bonus percent
Salary Plus Target Annual Bonus
Employee-related Liabilities, Current, Total
Employee-related Liabilities, Current
Accrued payroll and related expenses
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Cash flows from financing activities:
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term
Expected term (in years)
Fair Value, Recurring [Member]
Fair Value, Measurements, Recurring [Member]
Entity Ex Transition Period
Entity Ex Transition Period
US federal R&D tax credits
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
Other Restructuring [Member]
Other
Agreement termination period upon written notice.
Agreement Termination Period Upon Written Notice
Agreement termination period upon written notice
Equity Components [Axis]
Series A, B, C and D Convertible Preferred Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term
Exercisable at March 31, 2026
Nonoperating Income (Expense)
Total other income (expense), net
Equity Component [Domain]
Equity Component
Asset Class [Axis]
Asset Class
Deferred revenue, non-current
Deferred Revenue, Noncurrent
Deferred Revenue, Noncurrent, Total
Preferred Stock, Accretion of Redemption Discount
Accretion of beneficial conversion feature
Government Contracts.
Government Contracts [Table]
Government Contracts [Table]
Machinery and Equipment [Member]
Manufacturing Equipment [Member]
Collaboration revenue related party
Collaboration revenue related party
Collaboration revenue - related party
Common stock sold to cover employee taxes, Shares
Common Stock Sold to Cover Employee Taxes, Shares
Common Stock Sold to Cover Employee Taxes, Shares
US federal net operating losses
Deferred Tax Assets, Operating Loss Carryforwards, Domestic
Maximum [Member]
Maximum [Member]
Liabilities, Fair Value Disclosure, Total
Liabilities, Fair Value Disclosure
Derivative liabilities
Maximum received fund
Maximum Received Fund Amount
Maximum received fund amount.
Statistical Measurement [Axis]
Statistical Measurement
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Exercised
Common stock to be issued
Common Stock, Value, Issued, Ending Balance
Common Stock, Value, Issued, Beginning Balance
Common Stock, Value, Issued, Total
Common stock, $0.001 par value; 120,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 57,891,493 shares issued and outstanding as of March 31, 2026 and 56,414,657 shares issued and outstanding as of December 31, 2025
Sales milestone events
Sales milestone events
Sales milestone events
Cash and Cash Equivalents [Abstract]
Cash equivalents:
Number of Patients
Number of Patients
Number of Patients
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Comprehensive loss:
Potential amount increase in committed funding.
Potential Amount Increase In Committed Funding
Potential amount increase in committed funding
Gain (Loss) on Sale of Derivatives
Change in fair value of derivative liability
Change in fair value of derivative liability
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
Impairment of Long-Lived Assets
License agreement milestone payments upon achievement of specified pivotal condition.
License Agreement Milestone Payments Upon Achievement Specified Pivotal Condition
Potential milestone payments upon achievement of specified condition
Other Nonoperating Income (Expense) [Abstract]
Other income (expense):
SPR720
SPR720 [Member]
SPR720 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Expected volatility
Preferred Stock, Shares Authorized
Preferred stock, shares authorized
Professional and Consultant Fees [Member]
Professional and Consultant Fees [Member]
Professional and consultant fees
Unvested RSUs and PSUs
Unvested RSUs and PSUs [Member]
Unvested RSUs and PSUs [Member]
Potential Amount of Uncommitted Funding
Potential Amount of Uncommitted Funding
Potential Amount of Uncommitted Funding
Entity Registrant Name
Entity Registrant Name
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net
Transfer of financial asset into level 3 of fair value
Significant financing component
Significant financing component
Significant financing component
Other Nonoperating Income (Expense), Total
Other Nonoperating Income (Expense)
Other income (expense), net
Series D Preferred Stock [Member]
Series D Preferred Stock [Member]
Subsequent Events [Abstract]
Income tax expense
Income Tax Expense (Benefit)
Income Tax Expense (Benefit), Total
Income tax benefit (expense)
Measurement Frequency [Axis]
Measurement Frequency
Sales agreement.
Sales Agreement [Member]
Sales Agreement [Member]
Proceeds from the issuance of common stock, net of issuance costs
Proceeds from sale of common stock to related party
Proceeds from the issuance of common stock, net of issuance costs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Concentrations of Credit Risk and of Significant Suppliers
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive gain (loss)
Payments made
Payments made
Payments for Restructuring
Assets
Total assets
Property, Plant and Equipment [Table]
Schedule Of Property Plant And Equipment [Table]
Income Statement [Abstract]
Restructuring Cost [Table]
Revenue interest financing text block.
Revenue Interest Financing Text Block
Liability Related to the Sale of Future Royalties
Share-Based Payment Arrangement [Policy Text Block]
Share-Based Compensation
Second Milestone [Member]
Second Milestone [Member]
Selling, General and Administrative Expenses [Member]
General and administrative
Stock Issued During Period, Shares, New Issues
Issuance of stock, shares
Issuance of common stock, net of issuance costs, shares
Discount on Obligations
Discount on Obligations.
Discount on Obligations
Earnings Per Share, Diluted
Earnings Per Share, Diluted, Total
Net loss per share attributable to common stockholders, diluted
Potential contract amount awarded.
Potential Contract Amount Awarded
Potential contract amount awarded
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]
City Area Code
City Area Code
Other comprehensive income (loss)
Other Comprehensive Income (Loss), Net of Tax, Total
Other Comprehensive Income (Loss), Net of Tax
Options to purchase common stock.
Options To Purchase Common Stock [Member]
Options to Purchase Common Stock [Member]
Proceeds from government contract
Proceeds From Government Contract
Committed amount from government contract
Commercial manufacturing facility amortization service period.
Commercial Manufacturing Facility Amortization Service Period
Supervision fee amortization service period
License agreement future milestone payments.
License Agreement Future Milestone Payments
Future milestone payments
Deferred Revenue Disclosure [Text Block]
Deferred Royalty Obligation
Segment Reporting Information [Line Items]
Cash and Cash Equivalents, Policy [Policy Text Block]
Cash Equivalents
Deferred Revenue Disclosure [Abstract]
Property, Plant and Equipment, Net, Ending Balance
Property, Plant and Equipment, Net, Beginning Balance
Property, Plant and Equipment, Net, Total
Property, Plant and Equipment, Net
Property and equipment, net
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number
Outstanding as of March 31, 2026 - vested and expected to vest
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Cash, cash equivalents and restricted cash at end of period
Cash, cash equivalents and restricted cash at beginning of period
Loss from operations
Operating Income (Loss)
Share based compensation award performance based vesting criteria one.
Share Based Compensation Award Performance Based Vesting Criteria One [Member]
Performance-based Vesting Criteria 1 [Member]
Non refundable up front payment received.
Non Refundable Up Front Payment Received
Nonrefundable upfront payments
Retained Earnings [Member]
Accumulated Deficit [Member]
Maximum potential funding from government contract
Maximum Potential Funding From Government Contract
Maximum potential funding from government contract
Share-based Payment Arrangement, Noncash Expense, Total
Share-Based Payment Arrangement, Noncash Expense
Share-based compensation
Payments of Stock Issuance Costs
Payment of financing/offering costs
Aggregate issue costs
Payment of offering and financing costs
Share based compensation award performance based vesting criteria two.
Share Based Compensation Award Performance Based Vesting Criteria Two [Member]
Performance-based Vesting Criteria 2 [Member]
SPR 206 [Member]
SPR 206.
S P R Two Zero Six [Member]
SPR206 [Member]
Operating Lease, Liability, Noncurrent
Non-current operating lease liabilities
Fair Value, Inputs, Level 1 [Member]
Level 1 [Member]
Class of Stock [Line Items]
Class Of Stock [Line Items]
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Net cash provided by financing activities
Beneficial conversion feature of Series C preferred stock
Beneficial conversion feature of stock.
Beneficial Conversion Feature Of Stock
Beneficial conversion feature of Series C preferred stock
Sublicense Fee Payable To Counterparty
Sublicense fee payable to counterparty.
Sublicense fee payable to counter party
License agreement milestone payments upon achievement of specified clinical, regulatory and commercial milestones.
License Agreement Milestone Payments Upon Achievement Of Specified Clinical Regulatory And Commercial Milestones
Potential milestone payment upon achievement of specified clinical, regulatory and commercial milestones
Investments, Fair Value Disclosure, Total
Investments, Fair Value Disclosure
Total marketable securities
Grant [Member]
Grant [Member]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Summary of Shares Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders
Revenue Recognition, Milestone Method [Table Text Block]
Schedule of remaining potential milestone payments
Research and Development Arrangement with Federal Government [Abstract]
Entity Interactive Data Current
Entity Interactive Data Current
Statement of Income Location, Balance [Domain]
Income Statement Location
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Cash flows from operating activities:
Furniture and Fixtures [Member]
Office Furniture and Equipment [Member]
Increase (Decrease) in Other Noncurrent Liabilities
Other long-term liabilities
Option Indexed to Issuer's Equity, Type [Domain]
Option Indexed to Issuer's Equity, Type
Entity Tax Identification Number
Entity Tax Identification Number
Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Stockholders' equity:
Revenues [Abstract]
Revenues:
Period of option granted on an agreement.
Period Of Option Granted On Agreement
Period of option granted on an agreement
Local Phone Number
Local Phone Number
Premium for commitment to sell common stock
Adjustments to Additional Paid in Capital, Premium for Commitment to Sell Common Stock
Amount of increase in additional paid in capital (APIC) resulting from the premium for commitment to sell common stock.
Reduction to research and development expense.
Reduction To Research And Development Expense
Reduction to research and development expense
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Denominator:
Management Transitions and Board Composition Description
Management Transitions and Board Composition Description
Management transitions and board composition description
Accounting Policies [Abstract]
Share based compensation arrangement by share based payment award non option equity instruments aggregate intrinsic value.
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Rollforwards
Aggregate Intrinsic Value
Revenue recognized
Revenue from Contract with Customer, Excluding Assessed Tax, Total
Revenue from Contract with Customer, Excluding Assessed Tax
Collaboration revenue
NIAID.
Niaid [Member]
Niaid [Member]
Authorized common stock value available for issuance.
Authorized Common Stock Value Available For Issuance
Common stock available for issuance
Class of Stock [Domain]
Class of Stock
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Weighted average period
Accrued Professional Fees, Current
Accrued professional fees
The Company Invoiced the First Milestone Payment
The Company Invoiced the First Milestone Payment
The company invoiced the first milestone payment
Research and development services performance obligation, Cumulative
Milestone Allocated Research And Development Services, Cumulative
Milestone Allocated Research And Development Services, Cumulative
Stock, Class of Stock [Table]
Schedule Of Stock By Class [Table]
Entity Emerging Growth Company
Entity Emerging Growth Company
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term
Outstanding as of March 31, 2026 - vested and expected to vest